PharmaShots | Incisive News in 3 Shots

Subscribe Now

Lantern Pharma

Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC

Lantern Pharma's LP-184 Gains the US FDA’s Fast-Track Designation to Treat TNBC

December 19, 2024

Lantern Pharma’s LP-184 Gains the US FDA’s Fast-Track Designation for Treating Glioblastoma

Lantern Pharma’s LP-184 Gains the US FDA’s Fast-Track Designation for Treating Glioblastoma

October 16, 2024

Lantern Pharma Reports the First Patient Dosing of LP-184 in the P-I Study for Advanced Solid Tumors Shots: The first patient has been dosed in the P-I trial evaluating the safety & tolerab

Lantern Pharma Reports the First Patient Dosing of LP-184 in the P-I Study for Advanced Solid Tumors Shots: The first patient ha...

September 26, 2023

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us